Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFM13 in relapsed or refractory CD30-positive lymphoma with cutaneous presentation
NCT03192202Phase 2Completed
- Start
- Jul 2017
- Primary completion
- Apr 2020
- Countries
- 1
01
Overview
A Phase 2 trial of acimtamig in CD30-positive lymphoma. Started Jul 2017; status: completed.
02
Drugs
acimtamig
03
Conditions
CD30-positive lymphoma
Beyond the preview
Go deeper on NCT03192202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192202.